Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 735-744

  Oetjens, Matthew T ^a   Denny, Joshua C ^a   Ritchie, Marylyn D ^b   Gillani, Niloufar B ^a   Richardson, Danielle M ^a   Restrepo, Nicole A ^a   Pulley, Jill M ^a   Dilks, Holli H ^a   Basford, Melissa A ^a   Bowton, Erica ^a   Masys, Dan R ^a   Wilke, Russell A ^a   Roden, Dan M ^a,c   Crawford, Dana C ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADME; biorepository; BioVU; CYP2D6; genotyping; Illumina; medicine rare variants; personalized medicine; precision

Indexed keywords

CLOPIDOGREL; CODEINE; CYCLOSPORIN; CYTOCHROME P450 2D6; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROLEPTIC AGENT; RAPAMYCIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TAMOXIFEN; WARFARIN;

ARTICLE; ASSAY; COPY NUMBER VARIATION; ELECTRONIC MEDICAL RECORD; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; PHARMACOGENOMICS; POLYPHARMACY; QUALITY CONTROL;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 CYP2D6; DNA COPY NUMBER VARIATIONS; ELECTRONIC HEALTH RECORDS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYPHARMACY; YOUNG ADULT;

EID: 84877655072     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.64     Document Type: Article

References (33)

1. Crawford DC, Ritchie MD, Rieder MJ. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics 8(5), 487-496 (2007).
2. Wells QS, Delaney JT, Roden DM. Genetic determinants of response to cardiovascular drugs. Curr. Opin. Cardiol. 27(3), 253-261 (2012).
3. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92(1), 87-95 (2012).
4. Peters EJ, McLeod HL. Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics 9(11), 1573-1577 (2008).
5. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol. Sci. 32(2), 72-81 (2011).
6. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14(1), 1-18 (2004).
7. Dumaual C, Miao X, Daly TM, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the affymetrix targeted genotyping system. Pharmacogenomics 8(3), 293-305 (2007).
8. Birdwell KA, Grady B, Choi L, et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22(1), 32-42 (2012).
9. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
10. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84(3), 362-369 (2008).
11. Dumitrescu L, Ritchie MD, Brown-Gentry K, et al. Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet. Med. 12(10), 648-650 (2010).
12. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17(1), 19-24 (2010).
13. Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81(3), 328-345 (2007).
14. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106(23), 9362-9367 (2009).
15. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007).
16. Grady BJ, Torstenson E, Dudek SM, Giles J, Sexton D, Ritchie MD. Finding unique filter sets in plato: a precursor to efficient interaction analysis in GWAS data. Pac. Symp. Biocomput. 315-326 (2010).
17. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 34, D617-D621 (2006).
18. International HapMap Consortium. The International HapMap Project. Nature 426(6968), 789-796 (2003).
19. Hewett M, Oliver DE, Rubin DL, et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res. 30(1), 163-165 (2002).
20. Rieder MJ, Livingston RJ, Stanaway IB, Nickerson DA. The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. Drug Metab. Rev. 40(2), 241-261 (2008).
21. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308-311 (2001).
22. Nakamoto K, Kidd JR, Jenison RD, et al. Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Pharmacogenet. Genomics 17(2), 103-114 (2007).
23. Mailman MD, Feolo M, Jin Y, et al. The NCBI dbGaP database of genotypes and phenotypes. Nat. Genet. 39(10), 1181-1186 (2007).
24. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1), 89-103 (2010).
25. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2), 321-326 (2012).
26. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).
27. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93(4), 324-325 (2013).
28. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90(2), 328-332 (2011).
29. Wilke R A, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012).
30. Wilke R A, Reif DM, Moore JH. Combinatorial pharmacogenetics. Nat. Rev. Drug Discov. 4(11), 911-918 (2005).
31. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) : clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2005).
32. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 11(5), 607-611 (2010).
33. Illumina. www.illumina.com